Investigating The Effect Of Altered Bag1   Gene Expression In Human Mcf7 Breast Cancer Cell Line by Behnoud, Sevil
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ISTANBUL TECHNICAL UNIVERSITY  GRADUATE SCHOOL OF SCIENCE 
ENGINEERING AND TECHNOLOGY 
M.Sc. THESIS 
MAY 2013 
 
INVESTIGATING THE EFFECT OF ALTERED BAG1   
GENE EXPRESSION IN HUMAN MCF7 BREAST CANCER CELL LINE 
 
Thesis Advisor: Assist. Prof. Dr. Gizem DİNLER DOĞANAY 
 
Sevil BEHNOOD 
Department of Advanced Technologies 
 
Molecular Biology, Genetics and Biotechnology 
 
 
 
Anabilim Dalı : Herhangi Mühendislik, Bilim 
Programı : Herhangi Program 
 
   
     
MAY 2013 
 
ISTANBUL TECHNICAL UNIVERSITY  GRADUATE SCHOOL OF SCIENCE 
ENGINEERING AND TECHNOLOGY 
INVESTIGATING THE EFFECT OF ALTERED BAG1   
GENE EXPRESSION IN HUMAN MCF7 BREAST CANCER CELL LINE 
 
M.Sc. THESIS 
Sevil BEHNOOD 
  (521101113) 
Department of Advanced Technologies 
 
Molecular Biology, Genetics and Biotechnology 
 
 
 
 
Anabilim Dalı : Herhangi Mühendislik, Bilim 
Programı : Herhangi Program 
 
Thesis Advisor: Assist. Prof. Dr. Gizem DİNLER DOĞANAY 
 
 
   
     
MAYIS 2013 
İSTANBUL TEKNİK ÜNİVERSİTESİ  FEN BİLİMLERİ ENSTİTÜSÜ 
 
İNSAN MCF7 MEME KANSERİ HÜCRE HATTINDA BAG1 GEN 
İFADESİNDEKİ DEĞİŞİMİN ETKİLERİNİN ARAŞTIRILMASI 
 
 
YÜKSEK LİSANS TEZİ 
Sevil BEHNOOD 
  (521101113) 
 
İleri teknologiler anabilim dali 
Molecular biology Genetiv ve Biotechnology Programı 
 
 
 
Anabilim Dalı : Herhangi Mühendislik, Bilim 
Programı : Herhangi Program 
 
Tez Danışmanı: Assist. Prof. Dr. Gizem DİNLER DOĞANAY 
  
 
v 
 
  
Thesis Advisor :  Prof. Dr. Name SURNAME  .............................. 
 İstanbul Technical University  
Co-advisor :   Prof.Dr. Name SURNAME   .............................. 
(If exists)  İstanbul Technical University 
Jury Members :  Prof. Dr. Name SURNAME  ............................. 
Yıldız Technical University 
Prof. Dr. Name SURNAME  .............................. 
Boğaziçi University 
Prof. Dr. Name SURNAME  .............................. 
Gebze Institute of High Technology 
(If exists)  Prof. Dr. Name SURNAME  .............................. 
Şişli Etfal Teaching Hospital 
(If exists)  Prof. Dr. Name SURNAME  .............................. 
Bilkent University 
Name-surname, a M.Sc./a Ph.D. student of ITU Institute of / Graduate School 
of...... student ID …....., successfully defended the thesis/dissertation entitled 
“…….THESIS TITLE…….…..”, which he/she prepared after fulfilling the 
requirements specified in the associated legislations, before the jury whose signatures 
are below. 
 
 
Date of Submission : 22 September 2009 
Date of Defense :  21 December 2009 
 
vi 
 
  
vii 
 
 
 
 
To my Best Parents (mama & baba)  & also my Best Advisor 
Imagine there’s NO Cancer                                                                         
It’s easy if we try, No pain or suffering                              
or waiting just to Die…. 
 
 
 
  
viii 
 
ix 
 
FOREWORD 
I would like to thank to my advisor Assoc. Prof. Dr. Gizem DİNLER - DOĞANAY 
for her motivations and supports throughout my master’s study. This project would 
not exist without her unlimited support and inspiration. I want to send my endless 
gratitudes to all the teachers who prepared me to these days.  And to my Best family 
who supported me all the time even when I was in Turky.  
 
 
 
 
May 2013                                 Sevil BEHNOOD 
 
MolecularBiologyGeneticbiotechnolog 
 
 
 
 
 
 
 
 
 
 
 
  
x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
TABLE OF CONTENTS 
Page 
FOREWORD .......................................................................................................... v 
TABLE OF CONTENTS ......................................................................................vii 
ABBREVIATIONS ............................................................................................. xiii 
LIST OF TABLES ................................................................................................ xv 
LIST OF FIGURES ............................................................................................ xvii 
SUMMARY .......................................................................................................... xix 
ÖZET.................................................................................................................... xxi 
1. INTRODUCTION ............................................................................................... 1 
1.1 General information about Bag-1 and its role in cell survival and apoptosis ........ 1 
1.2 BAG1 Structure in detail ..................................................................................... 4 
1.3 BAG1 Function in detail ..................................................................................... 6 
    1.4  RT PCR.......................................................................................................... 9 
    1.4.1 Introduction to realtime pcr .......................................................................... 9 
    1.4.2 Brief histrory of Nucleic acid detection and quantification ......................... 10 
    1.4.3 Real time PCR definition............................................................................ .. 10 
     1.5 Aim of study.................................................................................................... 10 
2.MATERIAL….………………………………………………….………............. 12 
     2.1 Material and Equipment…………………………………………………….. 13 
     2.1.1 Eqipment...................................................................................................... . 13 
2.1.2 Components and equipment.......................................................................... .... 13 
2.2 Methods............................................................................................................... 14 
  2.2.1 Preparation of cell culture........................................................................... .... 14 
 2.2.1.1 Establishing MCF7 cultures from frozen cells.......................................... . 14 
   2.2.1.1 cell counting.............................................................................................. .. 15 
   2.2.1.3 Hemocytometer method of cell counting.................................................. .. 16 
   2.2.1.4 cell passage ,cellfreezing.......................................................................... ... 17 
   2.2.2 siRNA transfection..................................................................................... .... 17 
    2.2.3 survival assay............................................................................................... .. 18 
   2.2.4 primer design............................................................................................... ... 18 
   2.2.4.1 step by step primer design........................................................................ ... 18 
   2.2.4.2 determine exon exon boundaries.............................................................. ... 19 
   2.2.4.3 design primer............................................................................................ ... 24 
   2.2.5 primer optimization..................................................................................... ... 21 
   2.2.6 relative quantification of gene expression................................................... ... 22 
   2.2.7 Rna quantification, isolation and reverse transcription reaction................. ... 22 
   2.2.7.1 RNA extraction........................................................................................ .... 22 
   2.2.7.2 Quantification of the isolated RNA.........................................................  ... 23 
   2.2.7.3 First strand CDNA synthesis.................................................................... ... 23 
   2.2.8 Referance gene validation........................................................................... ... 24 
      2.2.9 Preparation of PCR mix.............................................................................. . 24 
xii 
 
     2.2.10 qRT-PCR conditions.................................................................................. 25 
3. RESULTS AND DISCUSSION ........................................................................ 27 
   3.1 BAG1 silencing affected other genes expression level in MCF7 cell line ....... 27 
   3.2 Time optimization for siRNA effect ............................................................... 27  
   3.3 BAG1 silencing affected other gene expression level in MCF7 cellline .......... 29 
   3.3.1 Effect of Bag1 siRNA on BRAF gene expression in MCF7 cell line ........... 29 
      3.3.2 Effect of Bag1 siRNA on CRAF gene expression in MCF7 cell line......... 30  
     3.3.3 Effect of Bag1 siRNA on AKT gene expression in MCF7 cell line............ 31 
      3.3.4 Effect of Bag1 siRNA on BCL2 gene expression in MCF7 cell line. ........ 32          
   3.4. Disccusion .................................................................................................... 37 
  REFERENCES ................................................................................................... 38 
  APPENDICES .................................................................................................... 44 
   APPENDIX A. .................................................................................................... 45 
   APPENDIX B. .................................................................................................... 46 
      APPENDIX C. .................................................................................................... 47 
      APPENDIX D. .................................................................................................... 48 
      APPENDIX  E. .................................................................................................... 57 
      CURRICULUM VITAE ...................................................................................... 58 
 
 
 
 
xiii 
 
ABBREVIATIONS 
                       μg : Microgram 
                       μL           : Microliter 
μm  : Micrometer 
μM  : Micromolar 
Bad : Bcl-2-associated death promoter 
Bag-1 : Bcl-2-associated athanogene 
Bax : Bcl-2 homologous antagonist/killer 
Bcl-2 : B-cell lymphoma-2 
bp  : Base pair 
DMEM  : Dulbecco’s modified Eagle medium 
DMSO  : Dimethyl sulfoxide 
DNA  : Deoxyribonucleic acid 
E.coli  : Escherichia coli 
FBS  : Fetal bovine berum 
g  : Gram 
Kb  : Kilo base 
kDa : Kilo dalton 
L  : Liter 
LB  : Luria-Bertani Broth 
M  : Molar 
MAP : Mitogen-activated protein 
MAPK : Mitogen-activated protein kinase 
mg  : Miligram 
min  : Minute 
mL  : Mililiter 
mm  : Milimeter 
mM  : Milimolar 
mRNA  : Messenger ribonucleic acid 
NCBI  : National Center for Biotechnology Information 
ng  : Nanogram 
nM  : Nanomolar 
OD  : Optical Density 
PBS  : Phosphate Buffered Saline 
qPCR : Real time Polymerase chain reaction 
PI : Propidium Iodide 
pmol : picomole 
RNA  : Ribonucleic acid 
rpm  : Revolutions per minute 
siRNA : Small interfering RNA 
SOC  : Super Optimal Broth with catabolite repression 
TAP : Tandem Affinity Purification 
 
xiv 
 
 
 
 
 
  
xv 
 
 
LIST OF TABLES 
Page 
    Table 1.1: Primer design based on sequence………………………………….…...20 
    Table 2.2: Standard protocol for optimizing primer concentration………..………22 
    Table 3.3: Condition of q_PCR…………………………………………..…..……25 
  
xvi 
 
xvii 
 
LIST OF FIGURES 
Page 
Figure 1.1 A possible model of  RAF1,BAG1 and 14,3,3regulation........................4 
Figure 1.2 Schematic presentaiton of Bag-1mRNA..................................................6 
 Figure 1.3 BAG1 interaction partners and their molecular mechanisms...................9 
Figure 1.4: PCR starts with the denaturation of double strand DNA.......................11 
Figure 2.2.1 MCF-7/GFP Cell …….……………………………………………....14 
Figure 2.2.2 Useful number of the cells on a confluent flask.................................. 15 
Figure 2.2.3 chamber structure and cell counting process........................................16 
 Figure 2.2.6 Two sets of primers were  designed to amplify 2 gene……………...22                       
 Figure 3.1 qRT-PCR results obtained with GAPDH primers of total RNA isolated 
from wild-Type MCF7 Cell line…………………………………….25 
Figure 3.2 qRT-PCR results obtained with BAG1 primers of total RNA isolated  
fromWild Type MCF7 cell line………….….....................................26 
Figure 3.3 MCF-7 cell viability …………………………………………...............28     
Figure 3.4 Applied siRNA doses to MCF-7 cells ……………………………........29 
Figure 3.5 qPCR analysis of BRAF gene after siRNA treatment………………....30 
 
Figure 3.6 qPCR analysis of CRAF gene after siRNA treatment……………… ...31 
 
Figure 3.7 qPCR analysis of AKT gene after siRNA treatment…………………...32 
  
Figure 3.8 qPCR analysis of BCL2 gene after siRNA treatment………………….33 
   
Figure 3.9 qPCR analysis of BAX gene after siRNA treatment…………………..34 
 
Figure 3.10  qPCR analysis of BAD gene after siRNA treatment…………….......35 
 
Figure 3.11 qPCR analysis of 14,3,3 gene after siRNA treatment………………...36 
 
 
 
 
 
xviii 
 
 
 
 
  
xix 
 
 
 
 
 
 
 
INVESTIGATING THE EFFECT OF ALTERED BAG1   
GENE EXPRESSION IN HUMAN MCF7 BREAST CANCER CELL LINE 
 
SUMMARY 
Bcl-2 associated athanogene family (athano = against death in Greek) proteins are 
discovered by co-immunoprecipitation with Bcl-2 anti-apoptotic protein. Bag genes 
are evolutionally conserved and their homologues exist in yeasts, plants and animals. 
Bag family members control the cell homeostais in two different ways: (1) They 
contribute to maintain cell’s vital activity under normal and stress conditions via 
regulating both positively and negatively the cycle of Hsp70/Hsc70 molecular 
chaperone system. As a specific example, the direction of the cell balance under 
normal and stress conditions are maintained by competitive binding of Hsp70 or Raf-1 
to Bag-1. (2) They form complexes with transcription factors and nuclear hormone 
receptors which are controlling various physiological processes such as apoptosis, 
tumorigenesis, neural differentiation and cell cycle independent from Hsp70/Hsc70 
system. Expression levels and intracellular localization of Bag-1 family members 
differ in human in some complex diseases such as AIDS and Parkinson Disease in 
comparison with normal cells. For instance, the studies on breast cancer cells showed 
that Bag-1 expression can be used as a prognostic marker to monitor the disease 
progression.  Recently, it is postulated that high Bag-1 expression is also a prognostic 
marker for colon cancer.  Bag-1 isoforms appear to be differently localized in the cells. 
Main Bag-1 isoforms which are observed in humans are Bag-1S (36 kDa), Bag-1M 
(46 kDa) and Bag-1L (50 kDa). There is also another isoform of Bag-1, 29 kDa, 
however, since it is very scarce in the cell and thus is not consistently detected. Bag-1 
isoforms are produced by alternative translation initiation of single mRNA transcript; 
thereby they differ in their N-terminus related to translation initiation. All of Bag-1 
isoforms commonly include ubiquitin-like domain (ULD) and Bag domain (BD) in 
their C-terminus. Even though ULD domain function is not known clearly its 
evolutional conservation and relations with proteosom machinary indicates that ULD 
is necessary for stress tolerance. Bag-1L is localized in nucleus by means of its nuclear 
localization signal (NLS). NLS does not exist in Bag-1M which is cytosolic but can be 
translocated to nucleus via only companion proteins and Bag-1S which always 
presents in cytosol. N-terminus of Bag-1L and Bag-1M consist of eight TXSEEX 
repeats. It is shown that these repeats have a role in DNA binding and transcription 
activation depending on their nuclear localizations. Having less repeat sequences, Bag-
1S is the shortest isoform in the cells. 
Bag-1 has many critical roles in the cell through its interactions with certain target 
molecules to regulate carcinogenesis, differentiation, motility, proliferation, cell 
survival, apoptosis and transcription. Nuclear hormone receptors, Siah, CHIP, HGF 
receptor, Hsp70/Hsc70 complex, Bcl-2, and C-Raf (Raf-1) are known interacting 
partners of Bag-1. 
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 Cell survival and apoptosis are the two major pathways that Bag-1 is involved in. 
Bag-1 interactions with C-Raf or Bcl-2 are main mechanism that determine cell fate. 
Through these interactions Bag-1 helps to regulate the balance between cell death 
and cell survival. Although Bag-1 involvement in a great number of mechnanisms is 
known, the molecular details of these mechanisms and crosstalk between the 
pathways are not clear yet. The exact mechanism by which BAG1 inhibit apoptosis 
is unknown.In this study, we aim to understand how Bag1’s expression level affect 
Raf1 signaling proteins and some anti-and pro-apoptotic proteins that Bag-1 found to 
be influencing  
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İNSAN MCF7 MEME KANSERİ HÜCRE HATTINDA BAG1 GEN 
İFADESİNDEKİ DEĞİŞİMİN ETKİLERİNİN ARAŞTIRILMASI 
 
 
ÖZET 
Bcl-2 asosiye athano gen (Bag) ailesi (Yunanca ölüm karşıtı athanostan) proteinleri 
anti-apoptotik Bcl-2 proteini ile ko-immunopresipitasyon sonucu bulunmuşlardır. Bag 
genleri evrimsel olarak korunmuştur ve mayalarda, bitkilerde ve hayvanlarda 
homologları mevcuttur. Bag ailesi üyeleri iki farklı yolla hücre homeostazını kontrol 
eder: (1) Hem pozitif hem negatif şekilde Hsp70/Hsc70 moleküler şaperon sisteminin 
çalışma döngüsünü regüle ederek hücrenin yaşamsal faaliyetlerini normal ve stres 
koşullarında sürdürmesine katkıda bulunur. Buna spesifik bir örnek, hücrenin normal 
ve stres halleri arasındaki dengesinin yönünün Bag-1’e Hsp70 ya da Raf-1’in yarışmalı 
bağlanması sonucu sağlanması ile verilebilir. (2) Apoptoz, tümör oluşumu, nöronal 
farklılaşma ve hücre döngüsü gibi birçok fizyolojik süreci kontrol eden transkripsiyon 
faktörleri ve reseptörler ile Hsp70/Hsc70 sisteminden bağımsız olarak kompleksler 
oluşturur.  
Bag ailesi üyelerinin, insanlarda, kanser, AIDS ve Parkinson gibi kompleks 
hastalıklarda normal hücrelere kıyasla ekspresyon düzeylerinde ve hücre içi 
lokalizasyonlarında değişiklikler gözlenmektedir. Dolayısıyla, bu tip hastalıkları tahlil 
etmede Bag proteinlerinin hücre içi ekspresyonlarını ve lokalizasyonlarını incelemeye 
yönelik çalışmalardan yararlanılabilir. Örneğin, kanserli meme hücrelerinde yapılan 
çalışmalarla Bag-1 ekspresyonunun, hastalığın seyrinin izlenmesinde prognostik bir 
markör olarak kullanılabileceği gösterilmiştir. 
Hücrelerde Bag-1 izoformlarinin ekspresyon düzeyleri farklılık göstermektedir. Bu 
izoformlar hücrelerde bulunma sıklıklarına göre Bag-1S, Bag-1L ve Bag-1M olarak 
sıralanabilir. Buna rağmen tümörlü hücrelerde ekspresyon düzeyi en yüksek olan Bag-
1L izoformudur. Bunun nedeni ise Bag-1L’nin nüklear lokalizasyonuna bağlı olarak 
transkripsiyon faktörlerinin aktivitesini yönlendirmesi ve böylece hücre 
proliferasyonunu dolaylı yoldan  
 tetiklemesi olabilir.  Bag-1 izoformlarinin hücrelerde daha önce yapılmış çalışmalar 
sonucu  belirlenmiş etkileşim partnerleri; Bcl-2, Raf-1, Hsc70/Hsp70 sistemi, 
 nükleer hormon reseptörleri (NHR), ubikuitin/proteozom mekanizması ve DNA'dır.  
Bu etkileşimlerle Bag-1 izoformları, hücre büyümesi için kritik sinyal iletimi, 
proliferasyon, transkripsiyon gibi hücresel mekanizmalardan, hücre hareketi ve 
apoptoza varana kadar normal, malignan ve stres altında bulunan hücreler için önemli 
kontrol yolaklarında görev lmaktadır. 
 
Bag-1 izoformları, Hsp70/Hsc70 sistemini hem pozitif hem de negatif yönde kontrol 
ederek sırasıyla hücrelerin efektif bir şekilde protein üretebilmesi sonucu hücre 
xxii 
 
büyümesine ya da hücrelerin protein üretiminin yavaşlaması sonucu hücre ölümüne 
yol açabilir. Fakat bu kritik ayarlamada, henüz Bag-1’lerin Hsp70/Hsc70 sistemine 
tam olarak moleküler düzeyde nasıl bir kontrol mekanizması ile etkide bulunduğu 
net olarak bilinmemektedir. Kritik yolakların aydınlatılması yolunda literatürde yer 
alan örnekler aşağıda özetlenmektedir. 
Bag-1’in Hsc70 ile etkileşimi sonucu Bcl-2 ile bir kompleks oluşturduğu 
gözlemlenmiştir. Anti-apoptotik Bcl-2 ile Bag-1’in etkileşimi, öncelikle Bag-1’in C-
Raf (Raf-1) serin/treonin kinazı ile kompleks oluşturması sonucu gerçekleşir. Bunun 
sonucunda hücrenin yaşam ya da ölüm kaderini belirleyecek etkileşimlerin 
tetiklendiği ortaya çıkartılmıştır.  
Bu çalışmayla amaçlanan, MCF-7 meme kanseri hücre hattında Bag-1-ilişkili 
sağkalım mekanizmasının moleküler detaylarının aydınlatılmasıdır. Bu amaç 
doğrultusunda Bag-1’in ekspresyon seviyeleri değiştirilmiş ve hücreye etkisi 
incelenmiştir.  
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1. INTRODUCTION 
  
1.1 General information about BAG1 and its role in cell survival and apoptosis 
The oncogene BCL2 is a membrane protein that blocks a step in a pathway leading to 
apoptosis or programmed cell death. The protein encoded by this gene binds to 
BCL2 and referred to as BAG1 (BCL2-associated athanogene1). It enhances the anti-
apoptotic effects of BCL2 (for b lymphoma2) and represents a link between growth 
factor receptors and anti-apoptotic mechanisms. BAG1 isoforms have distinst 
subcellular localization and anti-apoptotic functions, but the exact mechanism by 
which BAG1 inhibits apoptosis are unknown. BAG1 as a multifunctional protein 
interacts with a wide range of target molecules to regulate apoptosis, proliferarion, 
transcription,  metastasis, and motility. BAG1 protein is expressed as three major 
isoforms, and one minor isoform. These four protein products are generated from a 
single mRNA with translation initiation from four different start codons through a 
leaky scaning mechanism. Isoforms of BAG1 cooperate with various other proteins 
and also DNA to facilitate the mentioned critical cellular processes. 
Cell death plays an important role in a wide variety of physiological circumstances 
essentially in all complex multicellular organisms. Several genes have been 
identified that participate as either inducers or repressors of programmed cell death. 
Among these, BCL2 is a blocker of cell death that was first discovered by virtue of 
its involvement in the t(14;18) chromosomal translocations found in the majority of 
non-hodgkins Bcell lymphoma (Sharp et al. 2004). Gene transfer-mediated 
overexpression of the BCL2 protein has demonstrated that BCL2 inhibits apoptosis 
induced by a variety of stimuli such as starvation of growth factors, Fas-stimulation, 
and cytotoxic T-cell killing, thus suggesting that BCL2 might function in a common 
pathway of apoptotic signaling for protection from cell death. So this protein 
regulates a distal step in a final common pathway for apoptotic cell death. Elements 
of this pathway appear to be well conserved throughout evolution (Takayama et al. 
1995). BCL2 has been shown to bind to several homolog proteins including Bax (for 
BCL2 associated protein), but BAG1 lacks sequence homology with BCL2 and its 
related proteins, indicating that it is not a member of the BCL2 protein family. BAG1 
therefore may represent the prototype of a novel type of anti-cell death gene. BAG1 
contains an ubiquitin-like sequence domain located at residues 37-73, which may be 
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important for a site for poly-ubiquitination followed by adenosine triphosphate-
dependent protein degradation. In contrast to BCL2 protein, BAG1 is ubiquitously 
expressed in almost all cells of different lineages. BCL2 overexpression is vitally 
important to its ability to block cell death. If partner proteins of BCL2 such as BAG1 
are present as insufficient levels or dominant inhibitors such as Bax or BCL-xs are 
produced at excessive levels, a mere increase in BCL2 protein levels may be 
inadequate to protect some types of cells from some kinds of cell death stimuli. 
BAG1 expression is frequently altered in a range of human cancers relative to normal 
cells. The expression of BAG1 has been associated with outcome in several cancer 
types (Cory et al. 2002). The prognostic impact of BAG1 has been investigated 
predominantly in breast cancer (Van Eijck et al. 2012). Breast cancer is the most 
common cancer that affect women. Estrogen play an important role in the 
development of breast cancer. Breast cell growth both normal and abnormal is 
stimulated by the presence of estrogen. Estrogen is mediated by estrogen receptors 
through estrogen response elements (ERE) and functions as a ligand dependent 
transcription factor. So hormonal therapy is a very effective treatment against breast 
cancer with hormone receptor positive patients, which blocks the ability of estrogen 
to turn on and stimulate the growth of breast cancer cells. 
Different BAG1 isoforms have distinct functions in modulating survival in breast 
cancer cells (Jun Chen et al. 2009). The anti-apoptotic function of BAG1 isoforms 
may be mediated through decreased BCL2 protein degradation (Liu et al. 2009). 
BAG1 and BCL2 act as a couple in ER positive breast cancer cells and cooperate in 
the regulation of apoptosis. Many growth factors are known to provide not only 
proliferative stimulus but also anti-apoptotic stimulus simultaneously through the 
ligand-specific receptors. Findings that BAG1 and BCL2 expression is regulated by 
the same signaling pathway in cytokine stimulation imply the functional significance 
of the cooperative expression of these two anti-apoptotic gene products (Youle et al. 
2008). BAG1 is constitutively expressed at low levels even without cytokine 
stimulation, whereas the level of BCL2 expression is under the detectable level 
(Wang et al. 1996). Overexpression of BAG1 alone could not prolong cell survival of 
a human T-cell line upon Fas-stimulation, but co-expression of both BAG1 and 
BCL2 did enhance resistance to apoptosis more than overexpression of BCL2 alone. 
So the synergistic effect of the BAG1 and BCL2 expression strongly suggests that 
the cooperative expression may be required for proceeding cell survival.  
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Cancers are believed to arise from a series of sequential mutations that occur as a 
result of genetic instability and/or environmental factors. It is known that normal 
stem cells have mechanisms that make them relatively resistant to chemotherapy, 
such as increased expression of BCL2 family proteins, increased expression of 
membrane transporters like breast cancer drug resistance protein, and multiple drug 
resistance. The expression of such proteins in tumorigenic breast cancer cells may 
make them inherently more resistant to current therapies. High levels of cytoplasmic 
BAG1 expression are detected in two thirds or more cases of breast cancer (Liu et al. 
2009). BAG1 may be phosphorylated under some conditions (Cato et al. 2001), but 
the functional significance of this and other potential post-translational modifications 
such as BAG1 ubiquitylation (Sourisseau et al. 2001) are poorly understood. BAG1 
overexpression in cancer may arise from hyperphosphorylation and acetylation of 
histones via the recruitment of 14-3-3 and histone acetyltransferases. Thus, the 
expression of BAG1 can be regulated by epigenetic mechanisms in nucleus. Further 
analysis of BAG1 promoter showed that it has a 272 bp long CpG island located 
between nucleotide positions 7472-7200, indicating that expression may be regulated 
by methylation/demethylation. Mostly, oncogenes are activated by DNA 
demethylation and this goes into a further assert that demethylation of BAG1 
promoter could contribute to the BAG1 overexpression in cancer cells. 
Despite the interesting and encouraging results obtained from studies of BAG1 in 
breast cancer, the ability of BAG1 overexpression to promote tumour formation in 
transgenic animals is yet to be tested. Such studies may produce compelling evidence 
that BAG1 plays a role in cancer development. 
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Figure 1.1: A possible model of  Raf-1, BAG1 and 14-3-3 regulation in cell survival          
and apoptosis, BAG1 has been suggested to act as a scafold protein to 
promote Bad phosphorylation and Raf-1 activation in neurons (Wood et 
al. 2009). 
 
1.2 BAG1 stucture in detail 
The BAG1 (Bcl-2 associated athanogene gene)  is located on human chromosome 9, 
band 13.3 a consisting of 7 exons (Takayama et al.1995). Its transcription may be 
initiated at one of the four promoters. The promoter has been dispersed along the 
positions -353 to -54 upstream of the first translational start codon and is a binding 
site for several transcription factors (Takayama et al. 2005). Translation at the 
internal AUG start site produce a major human BAG1 isoform: BAG1S, 230 aa. 36 
kDa. Alternative translational initiation start sites result in both longer forms of the 
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protein termed BAG1L, 50 kDa and BAG1M, 46 kDa, which initiate at upstream 
(66th) CUG and (279th) AUG codons, respectively, and shorter form or minor 
isoform 26 kDa at (504th) codon (since it is very scarce in the cell and thus is not 
consistently detected) (Gehring et al. 2006). Even though alternative translation 
mechanism is not yet clear, there are hypothesis that might explain for the 
mechanism of translation (Townsend et al. 2005). While Bag1L and Bag1M isoforms 
are translated via of 5’ cap structure of Bag-1 mRNA (Coldwell et al. 2001), Bag-1S 
isoform translation is dependent on an internal ribosome entry site (IRES). The 
ribosome binds to IRES element of the mRNA (Dobbyn et al. 2008). 
Various domains have been identified within BAG1 proteins, termed BAG domain, 
ULD domain and NLS domain, which are found in closely related proteins. BAG1 
protein is a homodimer but forms a heteromeric complex with HSP70/HSC70. 
Subcellular localization of Bag-1 isoforms is important for different biological 
mechanisms (Knee et al. 2001). The NLS (nuclear localisation signal) or (nuclear 
localisation sequence) domain of BAG1 mRNA is responsible for nuclear 
localization of BAG1L (Knee et al. 2001). BAG1M has both nuclear and cytosolic 
fractions of NLS according to the initiation site of translation of the mRNA 
(Brimmell et al. 1999). However, the localization of BAG1 isoforms can be regulated 
by cellular stress conditions which can cause relocalization of BAG1S and BAG1M 
to the nucleus (Townsend et al. 2002). These isoforms have different impacts on heat 
shock protein function, ubiqutination machinery and different transcriptional 
activities (Liu et al. 2009). C- terminal “BAG  domain” is found in all members of 
BAG protein family. BAG domain was first described as a conserved region which 
has about 50 amino acids (Takayama et al. 1999), but recent studies with advanced 
techniques like X-ray crystallograpghy, and multidimensional nuclear magnetic 
resonance (NMR) revealed that BAG1 domain has 110-124 amino acids and it 
consists of three anti-parallel α-helices, each approximately 30-40 amino acids in 
length (Briknarova et al. 2001). These helices provide interaction sites for other 
proteins; the first and second helices (α-1 and α-2) interact with the serine/threonine 
kinase Raf-1 and the second and third helices (α-2 and α-3) are the sites of 
interaction with the ATPase domain of Hsc70/Hsp70 (Takayama et al. 2001) and 
TNF-R1 (Antoku et al. 2001). As mentioned all three isoforms of BAG1 has a 
ubiquitin-like domain (ULD) (Bricknarova et al. 2001). Ubiquitin is a ubiquitous 76 
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amino acid protein that is covalently attached to protein substratess to target proteins 
for degradation by proteosome, the major non-lysosomal proteolytic complex in cells 
(Pickard et al. 2001). BAG1 has been shown to be ubiquitylated, but BAG1 proteins 
have relatively long half-lifes (Luders et al. 2000). Therefore BAG1 may play a role 
in coordinating ubiqıitin system instead of participating in conjugation reactions 
(Townsend et al. 2003). Although the ULD of BAG1 is structurally related to 
ubiquitin, BAG1 is not covalently attached to protein substrates. The ULD is 
essential for some but not all biologic functions of BAG1, and does appear to be 
significant for binding to the proteasome (Townsend et al. 2005). 
 
 
Figure1.2 : Schematic presentaiton of Bag-1 mRNA. Alternative translation sites of 
Bag-1 mRNA (A). Bag-1 isoforms with the binding domains (B) (Zheng 
et al. 2010) 
 
1.3 BAG1 function in detail 
BAG1 exhibits positive expression in many malignant tumors as an anti-apoptotic 
protein. BAG1 is multifunctional and the function of its individual isoforms may 
depend on both cell context and expression level.  
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All BAG1 isoforms by binding to BCL2 and heat shock protein 70s (Hsp70s) can 
modulate the function of these proteins in the cytosol, and also they bind to nuclear 
hormone receptors to inhibit hormone-induced apoptosis in the nucleus. BAG1 
isoforms and their subcellular location, thus their interaction partners are tissue 
specific. This might explain the variable effect of BAG1 protein on the outcome in 
different tumours. Different BAG1 isoforms have distinct functions (Jun chen et 
al.2009).In general, though, overexpression of BAG1 supresses activation of 
caspases and apoptosis (Hill et al. 2004). BAG1 can independently associate with 
Raf-1 and/or BCL2 and provide at least two potential mechanisms to promote 
survival (Song et al. 2001). Heat shock proteins are also required for cell survival 
and direct activation of these proteins may also be important in the pathways that 
modulate survival. Supression of apoptosis might contribute to the ability of BAG1 
to promote metastatic spread (Yawata et al. 1998).  
BAG1 potentiatiates the ability of BCL2 to inhibit apoptosis in breast cancer cells, 
but the exact mechanism by which BAG1 co-expression with BCL2 is currently 
unknown. BAG1 may affect the function of BCL2 by modulating its expression 
either at the transcriptional or post–translational level. The increased expression of 
BCL2 in cells transfected with BAG1 suggests that BAG1 function may be required 
to inhibit BCL2 protein degradation (Liu  et al. 2009). BAG1 may also function by 
directly influencing apoptosis of breast cancer cells in a BCL2-dependent manner. 
BCL2 proteins are thought to function, at least in part, by inserting into membranes 
and contributing to the formation or regulation of channels. It has been hypothesized 
that BAG1 may alter BCL2 function by acting on heat shock proteins which may 
facilitate conformational changes of BCL2 itself or proteins which might pass 
through the BCL2 dependent channels (Jill et al. 2012). Thus, breast cancer cells 
may be effectively get protected from apoptosis by a relatively low level of BCL2 in 
conjugation with significant BAG1 expression. In addition, BAG1 binds and 
modulates function of hepatocytes growth factor receptor which may also be 
important in breast carcinogenesis and represent another potential target of BAG1 in 
breast cancer.  
A second key function of BAG1 in cancer is the regulation of NHRs. BAG1 
potentiate activity of estrogen receptors (ER) which mediates proliferative, and 
survival responses to estrogen in hormone dependent breast cancers (Sharp et al. 
2004). The androgen receptor (AR) is important in prostate cancer and BAG1 
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increases the sensitivity of AR expressing cells to androgens. BAG1 also modulates 
the activity of the vitamin D3 receptor (VDR) and represses the activity of retinoic 
acid receptor (RAR), thyroid receptor (TR) and glucocorticoid receptor (GR) (Cato 
et al. 2001). The effects of BAG1 on some nuclear hormone receptors requires the 
BAG1 carboxy terminus and it is possible that NHR interactions of BAG1 involves 
chaperone molecules which are known to be important for NHR function (Takayama 
et al. 1998). This has been demonstrated most clearly for the AR. Effects on NHR 
may be partly through BAG1 triggered conformational changes mediated by heat-
shock proteins which may be important for altering hormone binding capacity or 
affinity. This is not the case for all NHRs. Biochemical and mutagenic analysis 
therefore suggest that there may not be a single mechanism to account for BAG1s 
modulation of nuclear hormone receptor activity (Cato et al. 2001). Although all 
BAG1 isoforms can interact with chaperone molecules and poss anti-apoptotic 
activity, regulation of NHR is frequently specific for the BAG1L and/or BAG1M 
proteins. For example, only BAG1L regulate the AR (Froesch et al. 1998) and ER 
(Cutress et al. 2002) whereas both BAG1L and BAG1M regulate GR. It is not clear 
whether the frequent specificity for the larger BAG1 isoforms stems from the nuclear 
localisation of these proteins or from a requirement for additional Hsc/Hsp70 
independent functions encoded by the amino-termini of these isoforms. For instance, 
alternatively, non-specific DNA binding mediated by basic amino-acid residues of 
the N-terminal NLS and/or transactivating activity of the larger BAG1 proteins might 
play a role in the stabilization of the receptor, DNA complexes and/or recruitement 
of transcription factors (Zeiner et al. 1999).  
Although Bag-1 predominantly functions to suppress apoptosis, most likely acting 
between the growth/survival receptors and the mitochondria, it also involves other 
regulatory points in the apoptotic cascade (Takayama et al. 2001). Independent of 
NHRs, BAG1 isoforms can directly interact with Hsc/Hsp70 chaperones to function 
as their nucleotide exchange factor. By the synergistic action of these proteins, 
efficient folding can be achieved in the cell. Simple regulation of the refolding action 
of Hsp70s by BAG1 is not sufficient for all the observed actions of BAG1, since 
other BAG1 protein regions are required for its biological functions. BAG1 may act 
as a scaffold molecule, to functionally link chaperone function with specific target 
molecules (Hohfeld et al. 2001). One of the interactions of BAG1 that may not occur 
through direct HSC70/HSP70 binding is with Raf-1. It is found in some of the 
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reports that Raf-1 and Hsp70 competitively bind to a similar site on BAG1 
(Sondermann et al. 2001). Since, though, some studies proved the otherwise, this 
contreversy needs to be clarified. It could be possible that Hsp70 levels would be 
important to determine the interaction profile of BAG1. High levels of HSP70 that 
accumulate in stressed cells may displace Raf-1 and this shuts down the important 
signaling path that promote cell survival and proliferation. Therefore, BAG1 
isoforms may act as a molecular switch in signaling pathways that direct cells toward 
different states depending on whether enviromental conditions are hospitable or 
stressful (Van Eijck et al. 2012).  
 
 
 
          Figure 1.3: BAG1 interaction partners and their molecular mechanisms 
 
1.4 RT-PCR 
1.4.1 An introduction to real-time PCR 
There are several ways to question a cell for changes induced by artificial or natural 
agents during a biological process. One way is to look for changes in cellular 
transcript levels that may indicate changes in the corresponding proteins, or looking 
for an increase in the level of expression from a transgene or the inhibition of 
expression of an endogenous gene by a siRNA is the question of interest. 
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Quantitative real-time PCR technology can be utilized to provide the required 
information.  
1.4.2 A brief history of nucleic acid detection and quantification 
Initially, nucleic acid quantification meant the addition of radiolabeled UTP or 
deoxythymidine triphosphate (dTTP) to cell cultures or one of many possible in vitro 
experimental preparations and measuring their incorporation into nucleic acids by 
TCA (trichoroacetic acid) precipitation.  It was now possible to specifically identify a 
particular gene or transcript by hybridization of a radioactively labeled probe to a 
membrane bearing DNA restriction fragments or RNA.  
In combining the reverse transcriptase (RT) reaction with the PCR, identification of a 
specific RNA transcript was now possible from very low copy numbers of starting 
material. Quantification of transcripts from sample unknowns became possible with 
the advent of competitive RT-PCR (Vu et al. 2000). Known amounts of the RNA 
product were spiked into the RT reaction and converted into cDNA along with the 
target sequence within the unknown sample. Subsequently, both the truncated 
standard and unknown target sequences were amplified using the PCR. The products 
on the gel were imaged following staining with ethidium bromide or SYBR Green I. 
Real-time quantitative PCR has become the most accurate and sensitive method for 
the detection and quantification of nucleic acids yet devised. This method has 
overcome most of the major shortcomings of the preceding ones. Using the 
specificity and sensitivity of PCR combined with direct detection of the target of 
choice utilizing fluorescently labeled primers, probes or dyes, the inherent problems 
of gels, transfer to a membrane, radioactive probe hybridization and the limitations 
of film as a detector have been eliminated. There are two problems for real-time PCR 
that still linger. They are 1) methods of quantification, i.e. kind of standard, assay 
quality and calculation methodology used and 2) how to properly normalize different 
samples to correct for differences in nucleic acid input from sample to sample. 
 
1.4.3 Real-time quantitative PCR  
Real-time PCR is the continuous collection of fluorescent signal from one or more 
polymerase chain reactions over a range of cycles. Quantitative real-time PCR is the 
conversion of the fluorescent signals from each reaction into a numerical value for 
each sample. 
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Figure 1.4: PCR starts with the denaturation of double strand DNA. After 
denaturation,  primers anneal to their complementary sequences on 
single strands. Synthesis of the new strands is catalyzed by special 
polymerases. In every reaction turn, two daughter double-stranded 
DNA is produced from  the parent strand.  
 
1.5 Aim of the study 
In this study, we aimed to elucidate the molecular mechanism of Bag-1-associated 
cell survival in MCF-7 breast cancer cells.We comprehensively investigate BAG1 
mediated changes in gene expression level by comparing the gene expression profile 
after BAG1 siRNA silencing in MCF7 human breast cancer cell line. To understand 
Bag-1 and its isoforms involvement in anti-apoptotic processes in MCF-7 breast 
cancer cells, we silenced Bag-1 gene using Bag-1 siRNA. We first analyzed Bag-1 
silencing effect on different apoptotic genes by qRT-PCR. Bag-1 silencing caused a 
decrease in Akt gene expression which is as a key gene for survival and also 
decreased Bcl-2, C-Raf, B-RAF and 14-3-3theta mRNA expression levels. Earlier 
immunoblotting results showed that Akt activation, which is a marker for cell 
survival, was lost by Bag-1 siRNA transfection, revealing complementarity between 
mRNA and protein levels. Studies on protein level analysis for C-Raf and Braf 
showed a significant downregulation of these proteins after Bag-1 silencing. We also 
studied the alterations on other pro-and anti-apoptotic proteins expression level with 
Bag-1 silencing to further understand the molecular details of BAG-1 involved 
apoptotic mechanism. We believe that once the molecules in the BAG-1 related 
apoptotic pathway is delineated, Bag-1 might be used as a marker for cancer studies 
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both for treatment and prognosis. our results seggest that BAG1 could be a target for 
cancer treatment. 
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2. MATERIALS and METHODS 
2.1 Materials and equipment 
2.1.1 Equipment 
The laboratory equipment used during this study is listed in Appendix A. 
2.1.2 Compounds, kits and buffers 
The compounds and commercial kits used during the study are listed in Appendix B; 
the recipes of buffers and media used in the experiments are given in Appendix C. 
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2.2 Methods 
2.2.1 Preparation of cell culture  
MCF-7 is a human breast cancer cell line that was first isolated in 1970 from the 
malignant adenocarcinoma breast tissue of a 69-year old woman. MCF-7 is the 
acronym of Michigan Cancer Foundation, referring to the institute in Detroit where 
the cell line was established. MCF-7 cells are useful for in vitro breast cancer studies 
because the cell line has retained several ideal characteristics particular to the 
mammary epithelium. These include the ability for MCF-7 cells to process estrogen 
via estrogen receptors. MCF-7 cells are also sensitive to cytokeratin. When grown in 
vitro, the cell line is capable of forming domes and the epithelial like cells grow in 
monolayers. Growth can also be inhibited using tumor necrosis factor alpha (TNF 
alpha). 
 
   Figure 2.2.1 MCF-7/GFP Cell Line. Left: GFP fluorescence; Right: Phase contrast    
(Biolab research 2012)  
 
Quality Control  
This cryovial contains at least 1.0×106 MCF-7/GFP cells as determined by 
morphology, trypan-blue dye exclusion and viable cell count. The MCF-7/GFP cells 
are tested free of microbial contamination.  
  
2.2.1.1 Establishing MCF-7 Cultures from Frozen Cells 
 
 Place 10 mL of complete DMEM growth medium in a 50 mL conical tube.  Thaw 
the frozen cryovial of cells within 1–2 minutes by gentle agitation in a 37°C water 
bath.  Decontaminate the cryovial by wiping the surface of the vial with 70% (v/v) 
ethanol.  Transfer the thawed cell suspension to the conical tube containing 10 ml of 
growth medium. Collect the cells by centrifugation at 1400 rpm for 3 minutes at 
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room temperature.  Remove the growth medium by aspiration. Resuspend the cells in 
the conical tube in 15 mL of fresh growth medium by gently pipetting up and down.  
Transfer the 15 mL of cell suspension to a T-75 tissue culture flask. Place the cells in 
a 37°C incubator at 5% CO2. Monitor cell density daily. Cells should be passaged 
when the culture reaches 95% confluence. Cultures need to be initiated with the same 
number of cells, therefore population density will effect the behavior of the cells in 
the same manner. According to this, the cells were seeded after counting. The useful 
numbers for cell culture shown in Figure: 2.2.2. There are various sizes and dishes 
and flasks used for cell culture. Some useful number such as surface area and 
volumes of dissociation solutions are given here. 
 
Figure 2.2.2. Useful number of the cells on a confluent flask. 
 
2.2.1.2 Cell counting 
Growing medium was removed and cells were detached by 1 mL Trypsin-EDTA 
treatment for 2 min at 37
o
C. Then trypsin-EDTA solution was inhibited by 10 mL 
medium and cells were suspended Then 10 μL suspension was taken and put onto the 
hemocytometer or bright line counting chamber, cells were counted as the number of 
cells per 25 square (1 mm
2
). 
2.2.1.3 Hemocytometer method of cell counting 
The hemocytometer cell counting method uses a specially crafted gridded-glass slide 
consisting of two chambers, each divided into nine 1 x 1 mm squares. A glass cover 
is supported by the grid, and the cell suspension is loaded via capillary action into the 
chamber. The cells lie over the grid occupying a volume of 0.1 µL for each 1 x 1 mm 
square, and are counted manually. The number of cells counted in a specific number 
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of squares and the dilution factor are used to calculate the original concentration in 
cells/mL. Proper sample preparation technique is critical when working with the 
traditional hemocytometer. The Glass hemocytometer, with its free cover slip, is 
subject to over-filling, resulting in cell numbers that are often higher than those 
produced by disposable, fixed cover slip hemocytometers. Careful, consistent sample 
loading must be performed to avoid over-filling. The cell suspension must also be 
properly diluted so that a reasonable number of cells (25 to 250) are placed in each 
square. The subjective nature of human manual counting can lead to wide variation 
in results. In addition, the procedure is tedious and requires careful cleaning and 
handling of the hemocytometer parts.  
 
                 Figure 2.2.3: chamber structure and cell counting process. 
The cell number calculation is given below:  
The number of cells per cubic millimeter: 
                          Number of cells counted per square millimeter x dilution if used x 10 
The number of cells per  millimeter: 
                 Number of cells counted per square millimeter x dilution if used x 10,000 
2.2.1.3 Cell passage  
After cells were lifted and cell density was determined (%80 and above), cells were 
put into the centrifuge tubes and centrifuged 1400 rpm for 3 min. The supernatant 
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was discarded and pellet was resuspended with culture medium and 1x10
6
 cells were 
transferred to clean culture flask T75. 
2.2.1.4 Cell freezing 
After cell passage, cells resuspended in medium were transferred to freezing tube 
with freezing medium for future experiments. Estimated cell number for per freezing 
tube was 1x10
6
 cell/mL. 
2.2.2 siRNA transfection 
Lipofectamine™2000 has been used successfully to transfect short interfering RNAs 
(siRNA) into mammalian cells for RNA interference (RNAi) studies (Gitlin et al., 
2002; Yu et al., 2002).  
Transfection conditions are provided for a MCF7 cell lines as a starting point, then 
we optimizing transfection conditions to obtain the best results for your target gene 
and siRNA. Santa Cruz human BAG1 siRNA was used for the silencing of Bag-1 
gene. Lyophilized siRNA stock was 330 μL RNAse-free water and diluted as a 
working solution for transfection. 40 pmol dilution of siRNA was optimum for MCF-
7 cells to silencing.  
Opti-MEM® Reduced Serum Medium was used for dilution of siRNA to form 
transfection comlex. Since Opti-MEM® Reduced Serum Medium is an improved 
Minimal Essential Medium (MEM) that allows for a reduction of Fetal Bovine 
Serum supplementation by at least 50% with no change to growth rate or 
morphology and it is also recommended for use with cationic lipid transfection 
reagents, such as Lipofectamine reagent, it was chosen as transfection medium. 
Lipofectamine 2000 of Invitrogen was used as lipid agent to increase permeability of 
cell membrane, and instructions of the manufacturer were followed. 
2.2.3 Survival Assay (Trypan Blue Dye Exclusion Assay)  
Trypan Blue is a vital dye of which reactivity is based on the fact that the 
chromopore is negatively charged and does not interact with the cell unless the 
membrane is damaged. According to the time points, cells were counted each day for 
4 days using dye exclusion assay. 0,5x10
5
 cells were seeded each well of the 6-well 
plate one day before transfection. 24, 48, 72 and 96 h after transfection, growth 
medium was removed and cells were washed with PBS, twice. Cells were trypsinized 
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and gathered by centrifugation. Then, cells were exposed to 0.4% (w/v) Trypan blue 
dye (50 µL) and DMEM (50 µL) at 1:1 ratio. Dual-chamber FisherLab 
hemacytometer was filled with 10 µL of cells from trypan blue-DMEM mixture, and 
under a light microscope, non-viable cells were observed as stained while viable cells 
excluded the stain. Stained cells were counted and plotted. 
2.2.4 Primer design 
Optimal design of the PCR primers is essential for accurate and specific 
quantification using real-time PCR. Primer detection is based on the binding of the 
SYBR GreenI dye into double-stranded PCR products, which is a sequence-
independent process. Primer design is very restrictive: the annealing temperature is 
limited to between 55 and 60°C, which correspond to the optimal working conditions 
for the Taq DNA polymerase enzyme, and the length of the PCR product has to be 
set between 80 and 150 bp. In the first step primer designed to determine the 
sequence that needs to be targeted by the PCR. And in The second step related genes 
identify and eliminate regions of high homology, which may further restrict the 
length of the sequence available. A third step in primer design for cDNA 
quantification requires the design to overlap exon–exon boundaries. 
2.2.4.1 Step by step primer design: ß-actin for a cDNA quantification assay 
Identify the target sequence Browse the human genome project database with ß-actin 
as the keyword to identify the sequence, chromosome location (7p22.1), mRNA 
accession number (X00351), mRNA length (1761 bp) and gene structure (5 exons). 
To choose a suitable accession number to base primer design on, use the graphic 
representation to select an mRNA that includes all the exons and has 5’ and 3’ 
sequence. restrict this sequence with regards to regions of homology with related 
genes (a-actin, γ1 and γ2-actin) Align these sequences to determine domain of 
homology. Use the alignment tools on the NCBI website (BLAST 2 sequences) to 
find homologies. 
2.2.4.2 Determine exon-exon boundaries 
Use the human genome browser, click on the accession number for the human 
mRNA corresponding to the full-length transcript (e.g. X00351). Click on the 
accession number at the top to display the sequence database information. Click on 
the accession number under ‘query’ in the mRNA/Genomic alignment section to 
19 
 
obtain 5’ and 3’ sequences, coding region, ATG and STOP codons, exon–exon 
boundaries. Avoid inconsistent splicing sites and polyadenylation signals. 
 
2.2.4.3 primers Design 
As a result the sequence available for designing primer to quantify the expression of 
ß-actin is restricted to two regions, between nucleotides 1 and 90 or between 
nucleotides 1208 and 1763. There is no exon boundary in the second region. The 
design should, therefore, be limited to the region between the first and second exons 
of the gene. Transfer this sequence to the primer design software (e.g. Primer 
Express from ABI) and proceed to design. 
Copy the mRNA sequence into a simple PCR document. Restrict the target sequence 
accordingly. Select the option for primer Tm (59°C) and amplicon length (80 to 
120). Keep the CG content at default settings and primer length below 24 bp. See if 
the software comes up with a possible primer pair. If not, use the primer test 
document and try to select sections of sequence manually. This sequence is very CG 
rich, therefore, select a region with A or T as 3’ for each primer. Elongate the primer 
in 5’ until reaching a Tm between 58° and 60°C. Lastly, BLAST the primers (limit to 
the human species and mRNA bank). If the restriction in the target position has been 
done thoroughly, the BLAST search should give no matches. Quite a lot of hits are 
nevertheless reported for these primers. Most of them are on anti-sense strands of 
cDNAs. If none of them comes in both the forward and the reverse primer BLAST 
searches, no PCR product can be generated from these hits. These primers are 
located in the 5’ of the mRNA. 
 
     Table 2.1: Primer design based on sequence alignment. 
PRIMER SETS: 
1.Name of the oligonucleotide: BCL2 variant alphamRNA-F 
Sequence (5' to 3'): 
TCCCTCGCTGCACAAATACTC 
2.Name of the oligonucleotide: BCL2 variant alphamRNA-R 
Sequence (5' to 3'): 
ACGACCCGATGGCCATAGA 
 
3.Name of the oligonucleotide: BAX variant alphamRNA-F 
Sequence (5' to 3'): 
CCAAGGTGCCGGAACTGA 
4.Name of the oligonucleotide: BAX variant alphamRNA-R 
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Sequence (5' to 3'): 
TCCCGGAGGAAGTCCAATG 
 
5.Name of the oligonucleotide: BAD variant 1mRNA-F 
Sequence (5' to 3'): 
GAGTGACGAGTTTGTGGACTCCTT 
6.Name of the oligonucleotide: BAD variant 1mRNA-R 
Sequence (5' to 3'): 
TGTGCCCGCGCTCTTC 
 
7.Name of the oligonucleotide: GAPDH variant 1 Mrna-F 
Sequence (5' to 3'): 
ATGGAAATCCCATCACCATCTT 
8.Name of the oligonucleotide: GAPDH variant 1 Mrna-R 
Sequence (5' to 3'): 
CGCCCCACTTGATTTTGG 
 
9.Name of the oligonucleotide: BAG1s.Mrna-F 
Sequence (5' to 3'): 
CCCCTCATTTGTTGGCTGTCT 
10.Name of the oligonucleotide: BAG1s.Mrna-R 
Sequence (5' to 3'): 
CAGTGCATCTGAGGACCTGAAA 
 
11.Name of the oligonucleotide: 14.3.3.Mrna-F 
Sequence (5' to 3'): 
GCGTGTGGTGATGATCGAAA 
12.Name of the oligonucleotide: 14.3.3.Mrna-R 
Sequence (5' to 3'): 
AAATGCCTCTTGGTAAGCTCCTT 
 
13.Name of the oligonucleotide: BRAF-F 
Sequence (5' to 3'): 
CTGGCCCGCTCATTGC 
14.Name of the oligonucleotide: BRAF-R 
Sequence (5' to 3'): 
CCGATTCAAGGAGGGTTCTG 
 
15.Name of the oligonucleotide: CRAF-F 
Sequence (5' to 3'): 
TTCAGTTTCCAGTCGGATGTCTAC 
16.Name of the oligonucleotide: CRAF-R 
Sequence (5' to 3'): 
CTCCCCCGTCATCAGTTCA 
 
17.Name of the oligonucleotide: AKT-F 
Sequence (5' to 3'): 
CTGAGACGCCCGGTACATG 
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18.Name of the oligonucleotide: AKT-R 
Sequence (5' to 3'): 
CCCCTGCCGGTCTGAATC 
 
2.2.5 Primer optimization  
The optimization of the primer concentration is essential. Each set of primers works 
best at a different concentration. Primer concentration is usually determined to be 
optimal when the specific amplification relative to primer-dimers is maximal, in a 
positive versus negative control experiment. Primer optimization differs from one 
type of assay to another. 
  Table 2.2 Standard protocol for optimizing primer concentration.
 
               
 
                  Figure 2.2.6: Two sets of primers were designed to amplify 2 gene 
                                         primers at concentration 300/300 or 200/200 work better 
 
2.2.6. Relative quantification of gene expression 
This is also an easy optimization procedure, but one is looking for the best possible 
conditions of amplification (lowest Ct) with a similar PCR efficiency for both the 
target and the endogenous control(s) as reference (usually several housekeeping 
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genes). The procedure consists of finding the most efficient primer concentration for 
both genes, followed by a comparison of efficiency between target and reference. 
The same optimization matrix can be set up to find appropriate primer concentration 
conditions (both for the target and the reference genes). Then, a serial dilution of the 
input cDNA(1/5, 1/50, 1/500…) is used to compare the efficiency of both PCR 
reactions in parallel. Ct values will be different between the target and the reference 
but one is looking for parallelism between the two standard curves. PCR efficiencies 
can be compared by relating the slope of the linear curve of C values plotted against 
the log-dilution. A perfect reaction has a slope of 3.3, which corresponds to an exact 
two-fold amplification at every cycle of the PCR between dilutions of a factor 10.  
 
2.2.7 RNA quantification, isolation and reverse transcription reaction 
2.2.7.1 RNA extraction  
Commercially available kits perform well enough, have the advantage of not 
requiring phenol extraction (with the exception of Trizol, Invitrogen Life 
Technologies) but are costly, we used High pure RNA isolation roche Kit. An 
important point is to verify the absence of genomic DNA contamination. A DNase 
treatment step may be included to follow RNA extraction as gDNA contamination 
may interfere with the assay.  
2.2.7.2 Quantification of the isolated RNAs 
The quantity and quality of the RNA isolation is very important for downstream 
steps. RNA is a very variable and unstable molecule and it is very open to the 
negative effects of RNase enzymes which occur almost everywhere. Therefore, it is 
very easy to lose RNAs during the process. Thus, we need to be sure about the 
healthy existence of RNAs in our tubes. On the other hand, for a standart reverse 
transcription reaction, same amount of sample RNAs need to be used. Therefore, a 
healthy measurement of these RNAs is a vital process for the fate of the study. 
According to these concerns, sterile working issues had been followed especially by 
using RNase disinfectant solution (RNase-ExitusPlus, Applichem, Denmark) on the 
working areas. RNAs are measured with Nanodrop ND 1000 V 3.3 (Thermo 
Scientific, Wilmington, USA) spectrophotometer. 
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2.2.7.3 First strand cDNA synthesis  
Synthesis of cDNA from mRNA is the first step of RT-PCR gene expression 
quantification. The quality of the cDNA is directly related to the quality of the RNA 
template. If possible, determine the RNA concentration of samples before using them 
in an RT reaction. using initiation with either oligo-dT Once prepared, first-strand 
cDNA should not be thawed and refrozen more than once. During PCR set-up, it has 
to be kept on ice and used immediately. Once the cDNA has been synthesized, it 
remains to be verified that no DNA contaminates the samples. As the assay to 
determine mRNA quantity is based on PCR, the assay to detect genomic DNA 
contamination also needs to be performed using PCR (an agarose gel would not be 
sensitive enough).  
A genomic DNA target may be used as control for the size of a potential genomic 
DNA contamination band. The primers ATG GCAAAT TCC ATG GCA and TGA 
TGA TCT TGA GGC TGT TGT C for the GAPDH gene generate an amplicon of 
285 bp from cDNA and an amplicon of 453 bp from genomic DNA.  
Thaw protoscript M-MuLV Tag RT-PCR Kit components and place on ice.the 10x 
buffer warmed briefly at 42c and votexed to dissolve any precipitate.its important to 
set up a –RT control reaction,to insure there is no DNA  contamination. Make the 
RNA/PRIMER/Dntp mix by combining the following components in a sterile Rnase 
free tube. Heat for 5 min at 70c .spin briefly and promptly chill on ice. Add the 
following components to the 16 microlitre RNA/PRIMER/dNTP solution and mix 
well by pipetting up and down.10x RT buffer, murine Rnase inhibitor,M-MuLV 
Reverse Transcriptase Nuclease-free H2o. Incubate the 20microlitre cDNA synthesis 
reaction at 42c for one hour. Inactive the enzyme at 80 c for 5 min. Bring the reaction 
volume to 50 microlitre with water. CDNA products stored at -20c. 
2.2.8 Reference gene validation 
A number of reference (housekeeping) genes have been described in the literature 
and are used at different frequencies. Suzuki and colleagues reviewed 452 papers 
published in 1999, in six major journals, which used real-time PCR for mRNA 
quantification (Suzuki et al. 2000) and found that the most frequently used reference 
gene was GAPDH (33%), followed by b-actin (32%) and 18S rRNA (14%). The 
importance of assay- and tissue-specific reference gene validation has also been 
illustrated by others (Huggett et al. 2005).The choice of a suitable reference gene is 
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dependent on the individual model and requires investigation of the appropriate 
literature. 
2.2.9 Preparation of the PCR MIX 
Lightcycler 480SYBR Green I MASTER KIT is ideally suited for hot start PCR 
applications. This kit allows very sensitive detection and quantification of defined 
DNA sequences. 
To prepare one 20 microliter standard reaction: First we need to thaw one vial of 
lightcycler 480SYBR Green I MASTER and water (pcr-grade) and prepare 10x 
concentrated solution of the PCR primers. Later in a 1.5 ml reaction tube, one has to 
prepare the PCR mix by pipetting up and down (vortexing should be excluded). To 
start the reaction on the multiwall plate, 15 microlitres of the PCR mix should be 
added to each well with 5 microlitre of the DNA template. After sealing the 
multiwell plate with the lightcycler sealing foil, program can be run. 
2.2.10 qRT-PCR conditions  
qRT-PCR is performed with LightCycler 480 Real-Time PCR instrument (Roche 
Diagnostics, Mannheim, Germany). Reaction conditions are listed here. 
Table 2.3: Conditions of qRT-PCR. 
 [
0
C] Time Ramp rate [
0
C/s] Cycles 
Denaturation 95 05 min 4,4 1 
Amplification 95 10 sec 4,4 45 
55 18 sec 2,2 
72 05 sec 4,4 
Cooling 40 10 sec 1,5 1 
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3. RESULTS and DISCUSSION 
3.1 Effect of BAG1 siRNA treatment on BAG1 gene expression in MCF7 cell 
line  
BAG1 mRNA levels were extrapolated from the standard curve generated by the 
amplification of serially diluted DNA standards of known concentrations of BAG1   
amplicon. The measured BAG1 mRNA levels were corrected for errors arising from 
differences in sample preparation and reverse transcription efficiencies using the 
expression levels of GAPDH housekeeping reference gene as an internal standard. 
Representative qRT-PCR results (cDNAs used in this reaction were obtained by total 
RNA isolated from wild-type MCF-7 cells) are shown to demonstrate that our primer 
sets for both GAPDH and BAG-1 are functional. We obtained reasonable Cp values 
that correspond well with the dilution ratios.  
 
A)  
B)  
 
Figure3.1: A) qRT-PCR results obtained with GAPDH primers of total RNA 
isolated from wild-type MCF-7 cells (red curve, Cp showing a dilution of 
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cDNA in 1:1 (v:v) ratio; green Cp showing a dilution of cDNA in 1:10 
(v:v); purple Cp showing a dilution of cDNA in 1:100 (v:v); yellow 
negative control) B) standard curve (slope:-3.468, efficiency: 1.942, 
y:28.14) 
                
Figure 3.2 : A) qRT-PCR results obtained with BAG1 primers of total RNA isolated 
from wild-type MCF-7 cells (red curve, Cp showing a dilution of cDNA 
in 1:1 (v:v) ratio; green Cp showing a dilution of cDNA in 1:10 (v:v); 
purple Cp showing a dilution of cDNA in 1:100 (v:v); yellow negative 
control) B) standard curve (slope:-2,710, efficiency: 2,339, y:30.66) 
3.3 Time-dependent BAG-1 siRNA optimization 
BAG1 mRNA expression was screened in MCF7 cell lines. Aberrant or high BAG1 
protein expression in MCF7 breast cancer cell line suggests it might play a role as an 
anti-apoptotic protein in this cell line. To address this issue, BAG1 was silenced in 
MCF7 cells. BAG1 siRNA was effective when administered between 24 h and 48 h 
(Figure 3.3). 
  
A) 
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Figure 3.3 : MCF-7 cell viability gets altered due to the changes of Bag-1 
expression level. Cell survival (trypan blue dye exclusion) assay 
revealed that viable cell numbers decreased by BAG1 silencing  
                 
3.3 BAG1 silencing affected other genes expression level in MCF7 cell line 
Monitoring how other gene levels were influenced by BAG1 silencing, we found a 
notable decrease in BCL2, B-Raf, C-Raf, AKT, and 14-3-3 expression when treated 
with siRNA targeting BAG1 after 48 h. On the other hand, we observed an increase 
in BAD and BAX gene expression.  
3.3.1 Effect of BAG1 siRNA treatment on B-Raf gene expression in MCF7 cell 
line  
B-Raf gene (proto-oncogene B-Raf) is a serine/threonine-protein kinase. B-Raf 
protein is involved in cell signaling to direct cells to growth. This protein was shown 
to be mutated in human cancers (Wang et al. 1996). Earlier studies of ours and others 
revealed that BAG-1 overexpression leads to the activation of Raf/MEK/ERK 
signaling pathway (Datta et al. 1996). In this pathway, it is observed that BAG1 
forms a complex with B-Raf, C-Raf, Hsp70, BCL2 to activate the downstream 
players of Raf/MEK/ERK signaling pathway. So it is very interesting to study the 
expression profile of the proteins that BAG1 forms a complex. When B-Raf mRNA 
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levels were investigated after BAG1 silencing, we observed a significant decrease 
(mean: 0.3576, std: 0.02277, *p<0.05) (Figure 3.5). The Raf serine/threonine kinases 
are effectors of Ras that function as MAP3Ks in the ERK phosphorylation cascade. 
Mammals express three Raf proteins: Raf-1 (C-Raf); A-Raf; and B-Raf. Analysis 
targeting B-Raf protein levels after 24 and 48 h BAG-1 siRNA treatment also 
showed a similar profile; having a significant decrease in B-Raf levels (Demir et al., 
unpublished results). Therefore a decrease in the transcript levels correlate well with 
the earlier observation done on the protein levels of B-Raf. 
 
 
Figure 3.5: qPCR analysis of B-Raf gene after BAG-1 siRNA transfection of MCF-7 
cells (mean: 20.96, std: 0.03535, *p < 0.05, 0.025) 
 
3.3.2 Effect of BAG1 siRNA treatment on C-Raf gene expression in MCF7 cells 
C-Raf (Raf-1) is a member of the Raf kinase family of serine/threonine-specific 
protein kinases, from the TKL (Tyrosine-kinase-like) group of kinases, and is part of 
the ERK1/2 pathway as a MAP kinase kinase kinase (MAP3K) that functions 
downstream of the Ras subfamily of membrane associated GTPases. Since BAG1 
has known to interact with C-Raf under anti-apoptotic conditions, we wanted to 
investigate how BAG1 gene silencing affects C-Raf gene expression. We observed a 
significant decrease in the C-Raf transcript levels (mean: 0.06737, std: 0.05517, *p 
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<0.05) after Bag-1 silencing treatment was applied for 48 h (Figure 3.6). When 
protein levels of this protein were studied under BAG-1 silenced MCF-7 cells, we 
observed a dramatic decrease as well (Demir et al., unpublished results).    
Our results demonstrated that the decrease in expression levels of BAG1 gene in 
MCF7 cancer cell line through siRNA interference process causes a decrease in C-
Raf mRNA expression levels. This finding may reveal how a shift away from 
survival can be modulated.  
 
 
 
 
Figure 3.6: qPCR analysis of C-RAF gene after BAG-1 siRNA treatment in MCF-7 
cells (mean: 22, std: 0.01414, *p < 0.05, 0.01) 
 
3.3.3 Effect of BAG1 siRNA treatment on AKT gene expression in MCF7 cell 
line 
AKT1, AKT2, and AKT3 make up a family of serine/threonine kinases, often 
activated downstream of growth factor receptors and PI 3-Kinase. Each AKT family 
member contains an N-terminal pleckstrin homology (PH) domain, a central kinase 
domain, and a C-terminal regulatory domain. They have putative roles in cell 
proliferation and survival, and AKT perturbations are thought to play an important 
role in tumorigenesis. AKT (also called Akt1)/ (PKB), plays a key role in apoptosis, 
and it is involved in cellular survival pathways, by inhibiting apoptotic processes. 
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AKT is also able to induce protein synthesis pathways, and is therefore a key 
signaling protein in the cellular pathways that lead to skeletal muscle hypertrophy 
and general tissue growth. Since it can block apoptosis, and thereby promote cell 
survival, AKT has been implicated as a major factor in many types of cancer. AKT 
could promote growth factor-mediated cell survival both directly and 
indirectly. BAD is a pro-apoptotic protein of the BCL-2 family. AKT could 
phosphorylate BAD on Ser136, which makes BAD dissociate from the BCL-2/BCL-
X complex and loses the pro-apoptotic function. AKT could also activate NF-κB via 
regulating IκB kinase (IKK), thus result in transcription of pro-survival genes. When 
we analyze BAG1silencing effect on AKT gene expression level as a marker for cell 
survival, we observed a decrease in its expression level (mean: 0.5535, std: 0.546, 
p>0.05) (Figure 3.7), so we can hypothesize that with a decrease in BAG1 level, cell 
promptly decreases AKT levels to escape from survival and direct the cell toward 
apoptosis leading to elevated percentage of cell death.  
 
     
Figure3.7: qPCR analysis of AKT gene after BAG-1 siRNA treatment in MCF-   
cells (mean: 29.01, std: 0.07071, p > 0.05, 0.05) 
 
3.3.4: Effect of BAG1 siRNA treatment on BCL2 gene expression in MCF7 cell 
line 
When BAG1 was silenced, BCL2 transcript levels were sharply reduced (Figure 3.8). 
As known, BAG1 functions by directly influencing apoptosis of breast cancer cells in 
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a BCL2 dependent manner. BCL2 is an anti-apoptotic protein and its mRNA level 
decrease points to a direction away from survival in the cancerous cells.  
 
Figure 3.8: qPCR analysis of BCL2 gene after siRNA treatment (mean: 22.86, std: 
0.02121, *p < 0.05, 0.015)   
 
3.3.5 Effect of BAG1 siRNA treatment on BAX gene expression in MCF7 cell 
line. 
When BAG1 silencing was applied to MCF7 cells, BAX transcript levels were 
elevated (Figure 3.9). Since BAX, which is a protein of the BCL2 gene family, 
promotes apoptosis by competing with BCL2, it is expected to observe an 
enhancement in the BAX levels when a pro-survival gene was knocked-down. The 
BAX gene was the first identified pro-apoptotic member of the BCL2 protein family.  
BCL2 family members share one or more of the four characteristic domains of 
homology entitled the BCL2 homology (BH) domains (named BH1, BH2, BH3 and 
BH4), and can form hetero- or homodimers. BCL2 proteins act as anti- or pro-
apoptotic regulators that are involved in a wide variety of cellular activities. In 
healthy mammalian cells, the majority of BAX is found in the cytosol, but upon 
initiation of apoptotic signaling, Bax undergoes a conformational shift. Upon 
induction of apoptosis, BAX becomes organelle membrane-associated, and in 
particular, mitochondrial membrane associated. BAX is believed to interact with, and 
induce the opening of the mitochondrial voltage-dependent anion channel, VDAC. 
Alternatively, growing evidence also suggests that activated BAX and/or Bak form 
an oligomeric pore, MAC, in the outer membrane, resulting in the release of 
cytochrome c and other pro-apoptotic factors from mitochondria and leading finally 
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to the activation of caspases. The expression of BAX is upregulated by the tumor 
suppressor protein p53, and BAX has been shown to be involved in p53-mediated 
apoptosis. The p53 protein is a transcription factor that, when activated as part of the 
cell's response to stress, regulates many downstream target genes, including BAX. 
Wild-type p53 has been demonstrated to upregulate the transcription of a chimeric 
reporter plasmid utilizing the consensus promoter sequence of BAX approximately 
50-fold over mutant p53. Thus it is likely that p53 promotes BAX's apoptotic 
faculties in vivo as a primary transcription factor. However, p53 also has a 
transcription-independent role in apoptosis. In particular, p53 interacts with Bax, 
promoting its activation as well as its insertion into the mitochondrial membrane. 
BAX/BCL2 protein level of a cell is indicative of the cells apoptotic situation. From 
a parallel study (unpublished data), we determined that BAX/BCL2 ratio is 
dramatically increased in 48 h BAG1 siRNA transfected MCF-7 cells. mRNA levels 
and protein levels revealed similar results. Therefore, we think that with BAG1 
silencing cells are directed away from survival. 
 
 
Figure 3.9.  qPCR analysis of BAX gene after siRNA treatment (mean: 13.26, std: 
0.1344, p>0.05, 0.095 ) 
 
3.3.6 Effect of BAG1 siRNA treatment on BAD gene expression in MCF7 cell 
line 
When we analyzed BAD transcript levels, we observed a dramatic enhancement with 
BAG1 silencing (mean: 4.094, std: 1.726, p>0.05) (Figure 3.10). Since the error 
between our measurements is big, the result is not obtained as significant; more 
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experiments should be performed to lower the error. Overall, though, the trend in 
enhancement of BAD transcript is consistent. The BCL2-associated death promoter 
(BAD) protein is a pro-apoptotic member of the BCL2 gene family which is involved 
in initiating apoptosis. BAD is a member of the BH3-only family. After activation, it 
is able to form a heterodimer with anti-apoptotic proteins and prevent them from 
stopping apoptosis. BADs phosphorylation status determines its activation or 
deactivation: Dephosphorylated BAD forms a heterodimer with BCL2 and BCLXL, 
inactivating them and thus allowing Bax/Bak-triggered apoptosis. When BAD is 
phosphorylated by Akt/protein kinase B (triggered by PIP3), it forms the BAD-(14-
3-3)protein homodimer. This leaves BCL2 free to inhibit Bax-triggered apoptosis. 
BAD phosphorylation is thus anti-apoptotic, and BAD dephosphorylation (e.g., by 
Ca2+-stimulated Calcineurin) is pro-apoptotic. In a parallel study, when we checked 
the phosphorylation status of BAD in BAG1 overexpressed and silenced MCF-7 
cells, we observed that BAD gets phosphorylated and dephosphorylated from residue 
136, respectively. These results with the mRNA results revealed that pro-survival 
effects of BAG1 is suppressed under its silenced environment. BAG1 with our 
previous studies is partly affecting survival through varying the phosphorylation 
status of BAD.  
 
 
 
Figure 3.10:  qPCR analysis of BAD gene after siRNA treatment (mean: 16, std:  
0.02121, *p<0.05, 0.015) 
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3.3.5 Effect of BAG1 siRNA treatment on 14-3-3 gene expression in MCF7 cell 
line 
To study the effect of BAG1 on survival through BAD and 14-3-3 route, we 
analyzed 14-3-3 transcript levels. When BAG1 was silenced, we observed a decrease 
in the transcript levels of 14-3-3 (Mean:-, std: 0.3536, p>0.05) (Figure 3.11). 
Statistical analysis results are not acceptable, but when we compare the trend of 
change in 14-3-3 levels, we observe in all the measurements a decrease upon BAG1 
silencing. Further experiments should be performed to obtain consistent results. 
14-3-3 proteins are a family of conserved regulatory molecules expressed in all 
eukaryotic cells. There are at least seven distinct 14-3-3 genes in vertebrates: 
alpha/beta, epsilon, eta, gamma, theta, sigma, and zeta/delta. 14-3-3 proteins have the 
ability to bind a multitude of functionally diverse signaling proteins, 
including kinases, phosphatases and transmembrane receptors. 14-3-3 proteins act as 
key regulators of intracellular signal transduction through their ability to bind 
specific motifs containing phosphorylated serine or threonine residues.  
Since 14-3-3 proteins have diverse functions, BAG1 level alterations can affect 14-3-
3 levels differently.  One possible effect would be through the mentioned survival 
path. Further studies are necessary to delineate the entire network of communications 
between BAG1 and 14-3-3.  
 
 
 Figure 3.11:  qPCR analysis of 14.3.3 gene after siRNA treatment (Mean:20.02, std: 
0.03464, *p<0.05, 0.02) 
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BID is a member of the BCL2 family of proteins that regulates outer mitochondrial 
membrane permeability. BID is a proapoptotic member that causes cytochrome c to 
be released from the mitochondrial intermembrane space into the cytosol. In healthy 
cells, BID is cytosolic. In response to Fas Ligand or TNF-alpha, BID is cleaved by 
Caspase-8 and then relocates to the mitochondrial outer membrane. 
 
 
3.4 Disccussion 
 
Although some inconsistencies have been reported, there appear to be broad 
agreement that BAG1 is overexpressed in breast and non-small cell lung cancer and 
that this can correlate with clinical parameters and improved patient outcome. 
Studies have focused on breast cancer, non-small cell lung cancer and squamos cell 
carcinoma of the head and neck, and there are indications that BAG1 expression may 
also be altered in glioblastoma, cervical cancer and hematopoietic-malignancies. 
Further work, including prospective trials, are required to confirm the exciting 
possibility that BAG1 expression might be used as a prognostic marker in early 
breast cancer (Turner et al., 2001). Larger prospective studies should be more 
representive of the spectrum of breast cancer as a whole and have increased power to 
detect independent prognostic predictors in multivariate analysis,in particular in the 
presence of possible confounding associations such as tumor grade and Era status. As 
discussed by Turner, 2001, it is not immediately apparent why an antiapoptotic 
protein is associated with good prognosis. Multiple alteration contribute to 
carcinogenesis, and tumors that counter apoptosis by overexpressing BCL2 and 
BAG1 might represent one class of tumors. Other tumors may have disabled 
apoptotic response through accumulation of distinct changes, which might have more 
profound effects on cell death sensitivity or additionally affect proliferative pathway 
resulting in more aggressive tumour growth. It is also likely that the key targets of 
BAG1 will differ between cell types. A major factor that complicates the 
interpretation of  immunohistochemical analyses stems from the fact that there are 
multiple BAG1 isoform that can be functionaly distinct. Thus, we should not expect 
a simple pattern of changes in BAG1 expression in all cancer types due to 
differences in key BAG1 targets in different cell types. Despite the interesting and 
encouraging results obtained from studies of BAG1 in breast cancer, the ability of 
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BAG1 overexpression to promote tumour formation in transgenic animals is yet to be 
tested. Such studies may produce compelling evidence that BAG1 plays a casual role 
in cancer development. 
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APPENDIX A 
Laboratory Equipment 
 
Micropipettes        Eppendorf Research 2 μl 10 μl 20 μl 100 μl 200 μl 
1000 μl 
Pipettes         Serological Pipettes 2 ml, 5 ml, 10 ml, 25 ml 
Centrifuge                    Hettich ROTINA 420 Tabletop Centrifuge 
Vortex                    IKA MS3 Basic & Yellowline TTS2 
Laminar Flow       Thermo Scientific HERAsafe Cabinets Class II 
Incubator         Thermo Scientific Heraeus Function Line 
Refrigerators        Liebherr +4
0
C, FRYKA -30
0
C, Kirsch -30
0
C, 
                                          New Brunswick Scientific -80
0
C 
PCR Thermocyclers       Bio Rad DNA Engine Dyad Peltier Thermal Cycler 
         Eppendorf Mastercycler Thermal Cycler 
Spectrophotometer       Thermo Scientific Nanodrop ND 1000 V 3.3 
                                           + Software 
Cell Counter        Hemocytometer 
qRT-PCR System       Roche LightCycler 480 Real-Time PCR System 
         Software + geNorm algorithm data calculation 
Microscope        Axiovert 25 Zeiss + AxioCam Icc 1 + Software 
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APPENDIX B 
 
Kits & Chemicals 
Disinfectants   Bacillol AF - Cellculture 
    Applichem RNase-ExitusPlus 
Ethanol    Carl Roth 70%, 99.9% (RNA purpose) 
Trypsine    PAA 
PBS    PAA Dulbecco’s PBS (1x) without Ca & Mg 
β-mercaptoethanol  Applichem β-mercaptoethanol (RNA purpose) 
DMEM    PAA DMEM High Glucose (4,5 g/L) with L-Glutamin  
FCS    Invitrogen 
RNA Isolation  Roche high pure RNA isolation  Kit 
RT Reaction   Roche Transcriptor High Fidelity cDNA Synthesis Kit 
qRT-PCR    Roche LightCycler 480 Probes Master (2 Conc.) 
Primers    Sigma-Aldrich 
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APPENDIX C 
 
Buffers & Media 
Growth Medium 500 ml DMEM HighGlucose (4,5 g/L) with L-
Glutamine 
    50 ml FCS 
5 ml 100x Penicillin/Streptomycin 
Trypsine Solution  Trypsin/EDTA (0,025%/0,01%) 
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APPENDIX D 
 
Melt Curve Genotyping for B_RAF (Melt Curve Genotyping) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E1 BRAF wt 1/1 F1 BRAF wt 1/1 
E2 BRAF wt 1/10 F2 BRAF wt 1/10 
E3 BRAF wt 1/100 F3 BRAF wt 1/100 
E4 BRAF WT 1/1000 F4 BRAF WT 1/1000
E5 BRAF TS48 1/1 F5 BRAF TS48 1/1
E6 BRAF TS48 1/10 F6 BRAF TS48 1/10
E7 BRAF TS48 1/100 F7 BRAF TS48 1/100
E8 BRAF TS48 1/1000 F8 BRAF TS48 1/1000
50 
 
 
 
 
 
 
 
Melt Curve Genotyping for C_RAF (Melt Curve Genotyping) 
 
 
 
 
 
 
 
 
 
 
 
            
 
 
 
 
G5 CRAF wt 1/1 
G6 CRAF wt 1/10 
G7 CRAF wt 1/100 
G8 CRAF WT 1/1000
H5 CRAF TS48 1/1
H6 CRAF TS48 1/10
H7 CRAF TS48 1/100
H8 CRAF TS48 1/1000
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Melt Curve Genotyping for GAPDH (Melt Curve Genotyping) 
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Melt Curve Genotyping for BCL2 (Melt Curve Genotyping) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C1 BCL2 wt 1/1 D1 BCL2 wt 1/1 
C2 BCL2 wt 1/10 D2 BCL2 wt 1/10 
C3 BCL2 wt 1/100 D3 BCL2 wt 1/100 
C4 BCL2 WT 1/1000 D4 BCL2 WT 1/1000
C5 BCL2 WT 1/10.000 D5 BCL2 WT 1/10.000
C6 BCL2 TS48 1/1 D6 BCL2 TS48 1/1
C7 BCL2 TS48 1/10 D7 BCL2 TS48 1/10
C8 BCL2 TS48 1/100 D8 BCL2 TS48 1/100
C9 BCL2 TS48 1/1000 D9 BCL2 TS48 1/1000
C10 BCL2 TS 1/10.000 D10 BCL2 TS 1/10.000
C11 Neg CONTROL D11 Neg CONTROL
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Melt Curve Genotyping for BAG1 (Melt Curve Genotyping) 
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Melt Curve Genotyping for 14,3,3 (Melt Curve Genotyping) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E2  14,3,3 wt 1/1 
E3  14,3,3 wt 1/10 
E4  14,3,3 wt 1/100 
E5  14,3,3 wt 1/1000
E6  14,3,3 TS48 1/1
E7  14,3,3 TS48 1/10
E8  14,3,3 TS48 1/100
E9  14,3,3 TS48 1/1000
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Melt Curve Genotyping for AKT (Melt Curve Genotyping) 
 
 
 
 
 
 
 
 
 
 
C1 AKT wt 1/1 
C2 AKT wt 1/10 
C3 AKT wt 1/100 
C4 AKT WT 1/1000
C5 AKT WT 1/10.000
C6 AKT TS48 1/1
C7 AKT TS48 1/10
C8 AKT TS48 1/100
C9 AKT TS48 1/1000
C10 AKT TS 1/10.000
C11
C12 Wrong
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Melt Curve Genotyping for BAD (Melt Curve Genotyping) 
 
 
 
 
 
 
 
 
 
             
 
A1 BAD wt 1/1 
A2 BAD wt 1/10 
A3 BAD wt 1/100 
A4 BAD WT 1/1000
A5 BAD WT 1/10.000
A6 BAD TS48 1/1
A7 BAD TS48 1/10
A8 BAD TS48 1/100
A9 BAD TS48 1/1000
A10 BAD TS 1/10.000
A11
A12 NEGATIVE CONTROL
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Melt Curve Genotyping for BAX (Melt Curve Genotyping) 
 
 
 
 
 
  
C1 BAX wt 1/1 
C2 BAX wt 1/10 
C3 BAX wt 1/100 
C4 BAX WT 1/1000
C5 BAX WT 1/10.000
C6 BAX TS48 1/1
C7 BAX TS48 1/10
C8 BAX TS48 1/100
C9 BAX TS48 1/1000
C10 BAX TS 1/10.000
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APPENDIX E 
Table: Statistical analysis results obtained from qRT-PCR  
Genes 
   
P value 
BAG1 Mean 
 
0.004715 
 
 
Std. Deviation 0.001477 
 
 
Std. Error of Mean 0.001045 P value 
     B-Raf Mean 
 
20.96 
 
 
Std. Deviation 0.3535 
 
 
Std. Error of Mean 0.025 P value 
     C-Raf Mean 
 
22 
 
 
Std. Deviation 0.01414 
 
 
Std. Error of Mean 0.01 P value 
     AKT Mean  29.01  
 Std. Deviation 0.7071  
 Std. Error of Mean 0.05 P value 
     BCL2 Mean  22.86  
 Std. Deviation 0.02121  
 Std. Error of Mean 0.015 P value 
     BAX Mean  13.26  
 Std. Deviation 0.1344  
 Std. Error of Mean 0.095 P value 
     BAD Mean  16  
 Std. Deviation 0.02121  
 Std. Error of Mean 0.015 P value 
     14-3-3 Mean 
 
20.02 
 
 
Std. Deviation 0.03464 
 
 
Std. Error of Mean 0.02 P value 
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